Nitrofurantoin Mercury Pharmaceuticals

Nitrofurantoin, the active ingredient in Nitrofurantoin Mercury Pharmaceuticals, is a nitrofuran antibiotic presented as an oral tablet for oral use. It treats uncomplicated urinary tract infections in adult patients by targeting the bacteria that cause bladder infections, and is often chosen when alternative agents are unsuitable or resistance is a concern.

GNH USA supplies Nitrofurantoin Mercury Pharmaceuticals as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured medicines for healthcare providers and patients.

Nitrofurantoin is a nitrofuran antibiotic used to treat infections of the urinary tract. - Uncomplicated urinary tract infection: eliminates susceptible uropathogens and relieves dysuria and frequency. - Acute cystitis: provides rapid bacterial eradication, reducing symptom duration. - Prophylaxis of recurrent urinary tract infection: suppresses bacterial colonisation when used intermittently.

Nitrofurantoin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset occurring early in therapy. - Loss of appetite: reduced desire to eat. - Headache: transient cranial discomfort. - Diarrhoea: loose stools, usually self‑limiting. - Metallic taste: altered taste sensation. - Rash: mild skin redness or itching.

Serious or Rare Side Effects: - Pulmonary toxicity: interstitial lung disease presenting with cough and breathlessness. - Hepatic injury: elevated liver enzymes or jaundice. - Severe allergic reaction: anaphylaxis with swelling, hives, and airway compromise. - Hemolytic anemia: especially in patients with G6PD deficiency. - Peripheral neuropathy: numbness or tingling in extremities. - Stevens‑Johnson syndrome: severe skin blistering and detachment.

Before prescribing nitrofurantoin, clinicians should consider several safety precautions to minimise risk. - Renal function assessment: avoid use in patients with creatinine clearance below 60 mL/min due to insufficient urinary concentrations. - Pregnancy category B: use only when clearly needed, as safety data are limited. - G6PD deficiency: contraindicated because of risk of hemolytic anemia. - Elderly patients: monitor for signs of pulmonary toxicity and reduced renal function. - Drug interaction review: assess concomitant medications that may affect absorption or clearance. - Store at room temperature: keep in the original container, protect from moisture and light.

Nitrofurantoin can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Antacids containing magnesium or aluminum: markedly reduce nitrofurantoin absorption. - Probenecid: increases nitrofurantoin plasma levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Diuretics: can affect renal clearance, necessitating dose adjustment. - Oral contraceptives: may reduce contraceptive effectiveness, advise additional protection.